Research Grade Pavunalimab (DHD30408)

Wuhan Biolab Reagents was founded in 2021. Its core founding team comprises five tier researchers in the life sciences, graduates of Wuhan University, Huazhong University of Science and Technology, Huazhong Agricultural University, and other leading institutions. With over two decades of collective industry experience, the team has built solid capabilities in product development and applied technology, laying a robust technological foundation for the company.

Recognized as a National High-tech Enterprise and a National Technology-based SME, the company’s technical expertise has received authoritative endorsement. It also holds dual certification under ISO9001 and ISO13485 quality management systems, ensuring standardized quality control and reliable product performance. Leveraging globally advanced technology platforms, Biolab Reagents focuses on the global development and integration of high-quality biological reagents. It serves as the exclusive authorized partner in Asia for France’s AntibodySystem and as an agent for Sangon Biotech’s KleanAB brand. The company currently boasts a product portfolio of approximately 60,000 reagents, with core offerings spanning proteins, antibodies, and assay kits. These products primarily support research in areas such as oncology and neurological diseases, catering to diverse scientific needs.

Since its inception, Biolab Reagents has been committed to providing researchers and industrial clients in biomedicine with professional products and technical support. By offering premium research tools, the company empowers scientific exploration and contributes to innovation and breakthroughs in life sciences research.